Global footwear spending is near $500 billion, offering investment opportunities in niche markets. Nike leads in global shoe sales but faces challenges from innovative brands and inventory issues.

Bayer has filed for approval in the US for elinzanetant as a non-hormonal treatment for menopausal symptoms such as hot flushes, with a rival therapy from Astellas in its sights. The FDA submission is ...

All products featured on GQ are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. The world of sneakers ...